Lexicon Pharma (LXRX.US) Financial Statements - Balance Sheet/Income Statement/Cash Flow

Event Tracking

Dec5

Lescan Pharma to Present New Clinical Data on Sotagliflozin at CVCT 2025 Forum

13:30

Nov6

Lexicon Pharma released FY2025 Q3 earnings on November 6 Pre-Market EST, actual revenue USD 14.18 M (forecast USD 4.649 M), actual EPS USD -0.0351 (forecast USD -0.065)

14:30

Lexicon Pharma released FY2025 9 Months Earnings on November 6 Pre-Market EST, with actual revenue of USD 44.31 M and EPS of USD -0.1009

14:30

Oct30

Lexicon Pharma to release FY2025 Q3 earnings on November 6, Pre-Market EST, with forecasted revenue of USD 4.649 M and EPS of USD -0.065

00:08

Oct14

Analyst Joseph Pantginis Gives BUY Rating to Lescon Pharmaceuticals

14:56

Lescan Pharmaceuticals Advances Piravanserin for DPNP into Phase 3 Clinical Trial

12:01

Schedules & Filings

Schedules

Filings

Nov6

Earning Release(EST)

FY2025 Q3 Earning Release (USD) Revenue 14.18 M, Net Income -12.77 M, EPS -0.0351

Aug6

Earning Release(EST)

FY2025 Q2 Earning Release (USD) Revenue 28.87 M, Net Income 3.252 M, EPS 0.0089

May13

Earning Release(EST)

FY2025 Q1 Earning Release (USD) Revenue 1.262 M, Net Income -25.3 M, EPS -0.0698

Stock List

Top Gainers

Top Decliners

China Concepts

Symbol

Price

%Chg

Change